Australian Cancer Research Organization CTx Choose IDBS to Protect Patent Data
News Dec 12, 2008
IDBS has announced that the Australian pharmaceutical company, Cancer Therapeutics CRC (CTx, Melbourne, Australia), has selected both E-WorkBook and ActivityBase to manage its drug discovery and development on a global multi-site basis.
CTx invests in newly-discovered drug targets or compounds considered ‘high risk’ by many biotech and pharmaceutical companies.
Consisting of 11 different organizations collaborating in cancer therapeutics research, CTx works closely with leading Australian researchers and institutes to discover, protect and develop small molecule discoveries into preclinical drug candidates with commercial potential.
CTx chose ActivityBase because of positive user experience of the product at other participant CTx organizations. Seeking to replace its traditional paper lab notebooks with an integrated data management framework, CTx selected the E-WorkBook Suite to simplify the capture, analysis, storage and retrieval of research data. Because the E-WorkBook Suite can integrate data into one location accessible throughout the organization, CTx expects to see efficiency gains in terms of project workflow improvements and protection of IP and patent information.
Samantha Smith, Operations Manager for CTx, commented: “IDBS is obviously committed to the continuous improvement of their ELN. We receive quality and timely responses from the online support team, and interactions with IDBS technical support staff have been productive and helpful.”
Neil Kipling, founder and CEO of IDBS, commented: “IDBS’ investment in providing a complete solution to customers - rather than just software - has been recognized. Our continued investment in providing best-in-class products and our subsequent support for customers will help organizations such as CTx today and long into the future.”
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019